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INTRODUCTION
Cannabis (also known as marijuana, hashish, grass or 
hemp) is a natural product prepared from Cannabis 
plant, which is known to humankind since ancient 
times1, when it had been used as a medicine and a 
source of fibre2. In Europe, it was brought by Napo-
leonic soldiers returning from the Middle East, in the 
19th century.
The resin of the plant contains more than 480 
chemical compounds, including at least 84 psycho-
active substances known as cannabinoids3. The main 
psychoactive cannabinoid is Δ9- tetrahydrocannabinol 
(Δ9-THC or THC). 
Due to the effects of Δ9-THC and the other can-
nabinoids, cannabis is used nowadays mainly as a rec-
reational drug. The low price and easy accessibility of 
cannabis makes it one of the most widely abused rec-
reational substances, together with tobacco, caffeine 
and alcohol4. Its huge popularity is also related to the 
fact that people believe that cannabis is harmless. It is 
estimated that so far almost 77 million people in the 
European Union have used the drug at least once in 
their lifetime4. Most of them are young, aged between 
18-25 years1,5.
Despite the common perception about the drug’s 
safety more and more scientific studies focus on the 
cardiovascular complications of cannabis use. The 
extensive interest emerged as many case reports have 
been published over the last four decades associating 
the use of cannabis by young people with, potentialy 
lethal, cardiovascular disease2,6,7. The trigger of writ-
ing this short review was the results of toxicological 
analyses of some fatal cases. The cause of death of 
these cases was cardiac arrest and the only toxicologi-
cal finding was the detection of THC in blood and the 
THC metabolites in urine of the deceased.
In this short review we discuss the physiological 
and pathological effects of cannabis in human myo-
cardium with emphasis on the risk of developing a 
cardiovascular disease after cannabis use.
Physiological effects of cannabis use
The physiological effects of cannabis can either be 
acute or chronic7. Acute effects include a rapid and 
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dose-dependent increase in heart rate and blood pres-
sure that occurs as a result of beta-sympathetic stimu-
lation8. Chronic use of cannabis leads into tolerance to 
the previous effects due to a decrease in sympathetic 
activity and a dose-dependent increase to parasympa-
thetic activity7. Parasympathetic stimulation has the 
opposite effects to the cardiac function, causing bra-
dycardia and hypotension8. As it is already mentioned, 
the time-depentent effects of cannabis are strongly re-
lated to the dose that has been used in each case. Low 
to moderate doses tend to cause tachycardia and in-
creased blood pressure through the stimulation of the 
sympathetic nervous system whereas high doses lead 
to parasympathetic activation7.
Pathological effects of cannabis use
Several mechanisms have been proposed so far asso-
ciating cannabis use with chronic cardiovascular con-
ditions or acute cardiovascular events7,9,10. Most of the 
experimental and clinical outcomes support that: 
1) THC stimulates the production of catechol-
amines leading to proarrythmic effects. Several stud-
ies support that cannabis use can lead to profound 
sinus tachycardia and frequent premature ventricular 
beats5 and can also produce significant cardiac ar-
rhythmias. Rezkalla et al.11 also postulated that THC 
may be linked to genesis of ventricular tachyarrhyth-
mias by triggering activity in the Purkinje fibers.
2) Cannabis use by susceptible individuals can re-
sult in cardiac ischemia due to an increase in heart 
rate and cardiac workload that occurs via sympathetic 
stimulation. Additionally, increased sympathetic stim-
ulation can lead to myocardial infarction in otherwise 
healthy individuals that use cannabis (or those with 
low cardiovascular risk). Several case reports associ-
ating cannabis with myocardial infarction have been 
reported5.
3) Orthostatic hypotension and consequently syn-
cope can occur due to THC-mediated conduction of 
atrioventricular node, reduction of the left ventricular 
ejection time and decrease of peripheral vascular re-
sistance mainly in the sceletal muscle7.
4) The analgesic properties of THC may lead to 
a delay in seeking medical care for acute coronary 
events. Coronary heart disease mortality and coro-
nary artery calcification, which is an early indicator of 
coronary atherosclerosis have been reported through 
cannabis users7.
5) THC can increase blood carboxyhemoglob-
lin levels resulting in impaired oxygen supply to the 
heart, which results in a heart rate increase7. 
6) Cannabis smoking leads to the production of 
oxidant gases causing cellular stress which may in-
crease cardiovascular risk through the activation of 
platelets, the promotion of oxidized LDL formation, 
and induction of an inflammatory response10. On the 
other side, there are in vitro studies that support that 
Δ9-THC has a beneficial effect on cardiomyocytes, 
when used at low concentrations, protecting them 
from hypoxia during stress conditions12.
 However, parallel use of tobacco should always be 
considered when the the cannabis-associated risk of 
cardiovascular disease is studied, as there is a strong 
relation between tobacco cigarette smoking and can-
nabis use5.
CONCLUSIONS
As it was previously reported, cannabis use can lead 
to a number of acute or chronic cardiovascular effects 
that in some cases can possibly result in users’ death. 
It is obvious that there is a need for better informing 
and understanding of the possible effects of canna-
bis in human cardiovascular system. Future studies 
should focus on cardiovascular outcomes and effects 
of THC on arrhythmic, vascular, and atherosclerotic 
events.
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ΠΕΡΙΛΗΨΗ: Η κάνναβη αποτελεί μία από τις ευρύτερα διαδεδομένες σε χρήση ψυχοτρόπες ουσίες. Τα τελευταία χρόνια 
όλο και περισσότερες επιστημονικές μελέτες επικεντρώνονται στις καρδιαγγειακές επιπλοκές που σχετίζονται με τη χρήση 
της. Στην παρούσα σύντομη ανασκόπηση, παραθέτουμε τις φυσιολογικές και παθολογικές επιδράσεις της κάνναβης στο 
καρδιαγγειακό σύστημα, επικεντρώνοντας στον κίνδυνο ανάπτυξης καρδιαγγειακών παθήσεων μετά από χρήση της ουσίας.
Λέξεις Κλειδιά: Κάνναβη, Καρδιαγγειακές παθήσεις, Δ9- τετραϋδροκανναβινόλη.
Χρήση κάνναβης και καρδιαγγειακές επιπλοκές: Είμαστε αρκετά ενήμεροι;
Αγγελική Β. Κυριάζου1, Φώτιος Γ. Χατζηνικολάου1, Δημήτριος Κ. Κουτσούκης1,  
Αντώνιος Γ. Γούλας2, Αμβρόσιος Κ. Ορφανίδης1, Νικόλαος Γ. Ράικος1
1Εργαστήριο Ιατροδικαστικής και Τοξικολογίας, Ιατρική Σχολή, ΑΠΘ, Θεσσαλονίκη
2Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, ΑΠΘ, Θεσσαλονίκη
REFERENCES
